市場調査レポート

商品コード

1401931

ドライパウダー吸入器の2030年までの市場予測：製品別、機能別、適応症別、エンドユーザー別、地域別の世界分析

Dry Powder Inhalers Market Forecasts to 2030 - Global Analysis By Product (Multi Dose Dry Powder Inhalers and Single Dose Dry Powder Inhalers), Function, Indication, End User and By Geography

出版日: 2023年12月01日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF (Single User License)

USD 4,150 600,256円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回のみ可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (2-5 User License)

USD 5,250 759,360円

レポートPDFを同一事業所（所在地）内の5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (Site License)

USD 6,350 918,464円

レポートPDFおよびExcelを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は5回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Global Site License)

USD 7,500 1,084,800円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は10回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=144.64円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Stratistics MRCによると、世界のドライパウダー吸入器市場は2023年に214億8,000万米ドルを占め、予測期間中にCAGR 6.6％で成長し、2030年には336億米ドルに達すると予想されています。

ドライパウダー吸入器は、粉末状の薬剤を肺に直接吸入する医療機器です。喘息や慢性閉塞性肺疾患（COPD）のような肺関連疾患や呼吸器疾患の治療のために、頻繁に処方されます。定量噴霧式吸入器（MDI）とは対照的に、薬剤を供給するための推進剤を必要とせず、また、手と呼吸の協調を必要としないため、MDIの使用が困難な人にも適しています。

2020年4月に発表された"Common Respiratory Disorders"という論文によると、高齢者の約15％が喘息、慢性閉塞性肺疾患、その他の呼吸器疾患を患っているといいます。

呼吸器疾患の有病率の上昇

嚢胞性線維症、気管支炎、喘息、慢性閉塞性肺疾患（COPD）のような呼吸器疾患の有病率の増加は、効率的な吸入療法の必要性を直接後押しします。ドライパウダー吸入器は、肺に直接薬剤を供給する実用的で効果的な手段を提供するため、これらの疾患の治療手段として高い需要があります。呼吸器疾患を患う人の増加により、症状管理、増悪の回避、全体的な疾患管理の強化がより重視されるようになり、長期的な症状コントロールの維持と即時の緩和を提供する上で重要な役割を果たすため、市場の成長を後押しするドライパウダー吸入器の使用頻度が高まっています。

高い製造コストと適用の難しさ

病状管理の難しさによって引き起こされる服薬不遵守は、不十分な治療、病気の悪化、医療費の増加につながる可能性があります。患者がドライパウダー吸入器の取り扱いや装填を困難と感じる場合、ネブライザーや定量吸入器（MDI）のような代替吸入器の使用を選択する可能性があります。このような嗜好の変化によって、ドライパウダー吸入器の市場シェアや売上が影響を受ける可能性があります。ヘルスケアプロバイダーは、患者に適切な取り扱いと装填技術を指導するために、さらなる時間とリソースを割く必要があるかもしれないです。このような追加トレーニングの必要性により、患者教育プログラムの複雑性が増す可能性があり、その結果、ヘルスケアコストが上昇し、市場の成長を妨げる可能性があります。

予防医療と疾病管理への注目の高まり

ヘルスケアシステムとプロバイダーは、予防医療に重点を置くようになっているため、早期介入戦略に集中することが奨励されています。症状を管理し、増悪を食い止めるための予防的薬物療法を提供することで、呼吸器疾患の管理に大きく貢献しています。病気の予防と管理に焦点が移るにつれ、患者中心のケアモデルがますます重要になってきています。ドライパウダー吸入器は、使いやすく自己投与に適しているため、患者が呼吸器疾患を積極的に管理できるようにすることで、こうしたケアモデルを補完します。

激しい競合による原材料の入手可能性

ドライパウダー吸入器のような薬剤レジメンのコンプライアンスが不十分だと、COPDや喘息のような呼吸器疾患の治療が不十分になる可能性があります。肺機能の低下、増悪の頻度の増加、症状の悪化、入院リスクの増大はすべて、不完全または不規則な投与によって引き起こされる可能性があります。さらに、吸入困難などの様々な理由で患者がコンプライアンスを守らない場合、患者の嗜好の需要、処方率はすべて影響を受ける可能性があります。その結果、他の種類の吸入器よりも市場シェアが小さくなるかもしれないです。

COVID-19影響

パンデミック時には、COVID-19によって呼吸器の健康に対する意識が高まり、肺の健康が心配された結果、DPIを含む呼吸器治療薬の需要が急増しました。長期にわたる呼吸器疾患の患者は、必要な薬剤を入手し、治療計画を継続しようとしました。移動の制限や医療機関への受診の制限から、自宅での服薬自己管理の動きがあった。DPIは自己投与が可能で、使い勝手が良いため、定期的な通院が困難な呼吸器疾患の治療に最適な選択肢となった。

予測期間中、多用量ドライパウダー吸入器セグメントが最大となる見込み

多用量ドライパウダー吸入器セグメントは、粉末薬剤を肺に直接投与するために使用されるため、有利な成長が見込まれます。通常、複数回分の粉末薬剤を保持するリザーバーを使用するため、患者は時間をかけて複数回分を服用することができます。この装置では、あらかじめ複数の投与量を入れておくことができるため、患者に投与量の柔軟性を与え、あらかじめ決められた間隔で推奨量を服用することができます。患者のニーズを満たし、治療成績を向上させるため、この市場分野のメーカーは常に革新を続け、ドラッグデリバリーシステム、デバイスの人間工学、投与精度の向上に注力しています。

予測期間中、デジタル式吸入器デバイスのCAGRが最も高くなると予想されます。

デジタル操作吸入器デバイスセグメントは、予測期間中にCAGRが最も高くなると予測されます。これらの吸入器におけるデジタル技術は、データ追跡、接続性、処方スケジュールに対する患者のより良いアドヒアランスのような改善された機能を可能にします。したがって、吸入器デバイスにデジタルコンポーネントを追加する目的は、慢性閉塞性肺疾患（COPD）や喘息のような呼吸器疾患の管理方法を強化することです。デジタル操作の吸入器は、治療に対する個々の患者の反応や吸入器の使用パターンに関するデータを収集するため、個別化医療のアプローチをサポートすることができ、市場の成長を後押しします。

最大のシェアを占める地域

アジア太平洋地域は、呼吸器の健康と疾病管理を強化することを目的とした多くの政府プログラムやヘルスケア規制の結果、予測期間中最大の市場シェアを占めると予測されます。DPIやその他の効果的な吸入療法の採用は、支援政策によって頻繁に奨励されています。患者のアドヒアランスと管理は、DPIと、投与量追跡、リマインダー、接続性などの機能を提供するスマート吸入器などのデジタル技術との組み合わせによって改善されます。市場の進化は、このような患者中心のアプローチによって推進されています。

CAGRが最も高い地域：

喘息やCOPDなどの呼吸器疾患の罹患率が増加しているため、効率的な吸入治療の必要性が高まっています。DPIは、これらの疾患を治療するための実用的かつ効果的な薬剤投与手段を提供します。さらに、ドラッグデリバリーシステム、製剤、DPIのデザインにおける継続的な技術革新の結果、市場は成長しています。服薬アドヒアランスと有効性を高めるため、メーカーは常に携帯性に優れ、使いやすく、効率的なDPIの開発に取り組んでいます。

無料のカスタマイズサービス

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

企業プロファイル
- 追加市場プレーヤーの包括的プロファイリング（3社まで）
- 主要企業のSWOT分析（3社まで）
地域セグメンテーション
- 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
競合ベンチマーキング
- 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- 英国
- イタリア
- フランス
- スペイン
- その他欧州
アジア太平洋地域
- 日本
- 中国
- インド
- オーストラリア
- ニュージーランド
- 韓国
- その他アジア太平洋地域
南米
- アルゼンチン
- ブラジル
- チリ
- その他南米
中東とアフリカ
- サウジアラビア
- アラブ首長国連邦
- カタール
- 南アフリカ
- その他中東とアフリカ

第10章主な発展

契約、パートナーシップ、コラボレーション、合弁事業
買収と合併
新製品の発売
事業拡大
その他の主要戦略

第11章企業プロファイル

GlaxoSmithKline Plc
Boehringer Ingelheim GmbH
Cipla Limited
Chiesi Farmaceutici S.p.A
AptarGroup, Inc.
Iconovo AB
Mylan N.V
Pharmaxis
Teva Pharmaceutical Industries Limited
AstraZeneca Plc
Novartis AG
Elpen S.A
Vectura Group Plc
Beximco Pharmaceuticals Ltd
Hovione
MannKind Corporation
Sava Healthcare Ltd
3M Company
DPI Co., Ltd.

図表

List of Tables

Table 1 Global Dry Powder Inhalers Market Outlook, By Region (2021-2030) ($MN)
Table 2 Global Dry Powder Inhalers Market Outlook, By Product (2021-2030) ($MN)
Table 3 Global Dry Powder Inhalers Market Outlook, By Multi Dose Dry Powder Inhalers (2021-2030) ($MN)
Table 4 Global Dry Powder Inhalers Market Outlook, By Single Dose Dry Powder Inhalers (2021-2030) ($MN)
Table 5 Global Dry Powder Inhalers Market Outlook, By Function (2021-2030) ($MN)
Table 6 Global Dry Powder Inhalers Market Outlook, By Manually Operated Inhaler Devices (2021-2030) ($MN)
Table 7 Global Dry Powder Inhalers Market Outlook, By Digitally Operated Inhaler Devices (2021-2030) ($MN)
Table 8 Global Dry Powder Inhalers Market Outlook, By Indication (2021-2030) ($MN)
Table 9 Global Dry Powder Inhalers Market Outlook, By Pulmonary Arterial Hypertension (2021-2030) ($MN)
Table 10 Global Dry Powder Inhalers Market Outlook, By Chronic Obstructive Pulmonary Disease (COPD) (2021-2030) ($MN)
Table 11 Global Dry Powder Inhalers Market Outlook, By Asthma (2021-2030) ($MN)
Table 12 Global Dry Powder Inhalers Market Outlook, By Cystic Fibrosis (2021-2030) ($MN)
Table 13 Global Dry Powder Inhalers Market Outlook, By End User (2021-2030) ($MN)
Table 14 Global Dry Powder Inhalers Market Outlook, By Drug Stores (2021-2030) ($MN)
Table 15 Global Dry Powder Inhalers Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 16 Global Dry Powder Inhalers Market Outlook, By Hospitals (2021-2030) ($MN)
Table 17 Global Dry Powder Inhalers Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 18 Global Dry Powder Inhalers Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
Table 19 Global Dry Powder Inhalers Market Outlook, By Other End Users (2021-2030) ($MN)
Table 20 North America Dry Powder Inhalers Market Outlook, By Country (2021-2030) ($MN)
Table 21 North America Dry Powder Inhalers Market Outlook, By Product (2021-2030) ($MN)
Table 22 North America Dry Powder Inhalers Market Outlook, By Multi Dose Dry Powder Inhalers (2021-2030) ($MN)
Table 23 North America Dry Powder Inhalers Market Outlook, By Single Dose Dry Powder Inhalers (2021-2030) ($MN)
Table 24 North America Dry Powder Inhalers Market Outlook, By Function (2021-2030) ($MN)
Table 25 North America Dry Powder Inhalers Market Outlook, By Manually Operated Inhaler Devices (2021-2030) ($MN)
Table 26 North America Dry Powder Inhalers Market Outlook, By Digitally Operated Inhaler Devices (2021-2030) ($MN)
Table 27 North America Dry Powder Inhalers Market Outlook, By Indication (2021-2030) ($MN)
Table 28 North America Dry Powder Inhalers Market Outlook, By Pulmonary Arterial Hypertension (2021-2030) ($MN)
Table 29 North America Dry Powder Inhalers Market Outlook, By Chronic Obstructive Pulmonary Disease (COPD) (2021-2030) ($MN)
Table 30 North America Dry Powder Inhalers Market Outlook, By Asthma (2021-2030) ($MN)
Table 31 North America Dry Powder Inhalers Market Outlook, By Cystic Fibrosis (2021-2030) ($MN)
Table 32 North America Dry Powder Inhalers Market Outlook, By End User (2021-2030) ($MN)
Table 33 North America Dry Powder Inhalers Market Outlook, By Drug Stores (2021-2030) ($MN)
Table 34 North America Dry Powder Inhalers Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 35 North America Dry Powder Inhalers Market Outlook, By Hospitals (2021-2030) ($MN)
Table 36 North America Dry Powder Inhalers Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 37 North America Dry Powder Inhalers Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
Table 38 North America Dry Powder Inhalers Market Outlook, By Other End Users (2021-2030) ($MN)
Table 39 Europe Dry Powder Inhalers Market Outlook, By Country (2021-2030) ($MN)
Table 40 Europe Dry Powder Inhalers Market Outlook, By Product (2021-2030) ($MN)
Table 41 Europe Dry Powder Inhalers Market Outlook, By Multi Dose Dry Powder Inhalers (2021-2030) ($MN)
Table 42 Europe Dry Powder Inhalers Market Outlook, By Single Dose Dry Powder Inhalers (2021-2030) ($MN)
Table 43 Europe Dry Powder Inhalers Market Outlook, By Function (2021-2030) ($MN)
Table 44 Europe Dry Powder Inhalers Market Outlook, By Manually Operated Inhaler Devices (2021-2030) ($MN)
Table 45 Europe Dry Powder Inhalers Market Outlook, By Digitally Operated Inhaler Devices (2021-2030) ($MN)
Table 46 Europe Dry Powder Inhalers Market Outlook, By Indication (2021-2030) ($MN)
Table 47 Europe Dry Powder Inhalers Market Outlook, By Pulmonary Arterial Hypertension (2021-2030) ($MN)
Table 48 Europe Dry Powder Inhalers Market Outlook, By Chronic Obstructive Pulmonary Disease (COPD) (2021-2030) ($MN)
Table 49 Europe Dry Powder Inhalers Market Outlook, By Asthma (2021-2030) ($MN)
Table 50 Europe Dry Powder Inhalers Market Outlook, By Cystic Fibrosis (2021-2030) ($MN)
Table 51 Europe Dry Powder Inhalers Market Outlook, By End User (2021-2030) ($MN)
Table 52 Europe Dry Powder Inhalers Market Outlook, By Drug Stores (2021-2030) ($MN)
Table 53 Europe Dry Powder Inhalers Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 54 Europe Dry Powder Inhalers Market Outlook, By Hospitals (2021-2030) ($MN)
Table 55 Europe Dry Powder Inhalers Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 56 Europe Dry Powder Inhalers Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
Table 57 Europe Dry Powder Inhalers Market Outlook, By Other End Users (2021-2030) ($MN)
Table 58 Asia Pacific Dry Powder Inhalers Market Outlook, By Country (2021-2030) ($MN)
Table 59 Asia Pacific Dry Powder Inhalers Market Outlook, By Product (2021-2030) ($MN)
Table 60 Asia Pacific Dry Powder Inhalers Market Outlook, By Multi Dose Dry Powder Inhalers (2021-2030) ($MN)
Table 61 Asia Pacific Dry Powder Inhalers Market Outlook, By Single Dose Dry Powder Inhalers (2021-2030) ($MN)
Table 62 Asia Pacific Dry Powder Inhalers Market Outlook, By Function (2021-2030) ($MN)
Table 63 Asia Pacific Dry Powder Inhalers Market Outlook, By Manually Operated Inhaler Devices (2021-2030) ($MN)
Table 64 Asia Pacific Dry Powder Inhalers Market Outlook, By Digitally Operated Inhaler Devices (2021-2030) ($MN)
Table 65 Asia Pacific Dry Powder Inhalers Market Outlook, By Indication (2021-2030) ($MN)
Table 66 Asia Pacific Dry Powder Inhalers Market Outlook, By Pulmonary Arterial Hypertension (2021-2030) ($MN)
Table 67 Asia Pacific Dry Powder Inhalers Market Outlook, By Chronic Obstructive Pulmonary Disease (COPD) (2021-2030) ($MN)
Table 68 Asia Pacific Dry Powder Inhalers Market Outlook, By Asthma (2021-2030) ($MN)
Table 69 Asia Pacific Dry Powder Inhalers Market Outlook, By Cystic Fibrosis (2021-2030) ($MN)
Table 70 Asia Pacific Dry Powder Inhalers Market Outlook, By End User (2021-2030) ($MN)
Table 71 Asia Pacific Dry Powder Inhalers Market Outlook, By Drug Stores (2021-2030) ($MN)
Table 72 Asia Pacific Dry Powder Inhalers Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 73 Asia Pacific Dry Powder Inhalers Market Outlook, By Hospitals (2021-2030) ($MN)
Table 74 Asia Pacific Dry Powder Inhalers Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 75 Asia Pacific Dry Powder Inhalers Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
Table 76 Asia Pacific Dry Powder Inhalers Market Outlook, By Other End Users (2021-2030) ($MN)
Table 77 South America Dry Powder Inhalers Market Outlook, By Country (2021-2030) ($MN)
Table 78 South America Dry Powder Inhalers Market Outlook, By Product (2021-2030) ($MN)
Table 79 South America Dry Powder Inhalers Market Outlook, By Multi Dose Dry Powder Inhalers (2021-2030) ($MN)
Table 80 South America Dry Powder Inhalers Market Outlook, By Single Dose Dry Powder Inhalers (2021-2030) ($MN)
Table 81 South America Dry Powder Inhalers Market Outlook, By Function (2021-2030) ($MN)
Table 82 South America Dry Powder Inhalers Market Outlook, By Manually Operated Inhaler Devices (2021-2030) ($MN)
Table 83 South America Dry Powder Inhalers Market Outlook, By Digitally Operated Inhaler Devices (2021-2030) ($MN)
Table 84 South America Dry Powder Inhalers Market Outlook, By Indication (2021-2030) ($MN)
Table 85 South America Dry Powder Inhalers Market Outlook, By Pulmonary Arterial Hypertension (2021-2030) ($MN)
Table 86 South America Dry Powder Inhalers Market Outlook, By Chronic Obstructive Pulmonary Disease (COPD) (2021-2030) ($MN)
Table 87 South America Dry Powder Inhalers Market Outlook, By Asthma (2021-2030) ($MN)
Table 88 South America Dry Powder Inhalers Market Outlook, By Cystic Fibrosis (2021-2030) ($MN)
Table 89 South America Dry Powder Inhalers Market Outlook, By End User (2021-2030) ($MN)
Table 90 South America Dry Powder Inhalers Market Outlook, By Drug Stores (2021-2030) ($MN)
Table 91 South America Dry Powder Inhalers Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 92 South America Dry Powder Inhalers Market Outlook, By Hospitals (2021-2030) ($MN)
Table 93 South America Dry Powder Inhalers Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 94 South America Dry Powder Inhalers Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
Table 95 South America Dry Powder Inhalers Market Outlook, By Other End Users (2021-2030) ($MN)
Table 96 Middle East & Africa Dry Powder Inhalers Market Outlook, By Country (2021-2030) ($MN)
Table 97 Middle East & Africa Dry Powder Inhalers Market Outlook, By Product (2021-2030) ($MN)
Table 98 Middle East & Africa Dry Powder Inhalers Market Outlook, By Multi Dose Dry Powder Inhalers (2021-2030) ($MN)
Table 99 Middle East & Africa Dry Powder Inhalers Market Outlook, By Single Dose Dry Powder Inhalers (2021-2030) ($MN)
Table 100 Middle East & Africa Dry Powder Inhalers Market Outlook, By Function (2021-2030) ($MN)
Table 101 Middle East & Africa Dry Powder Inhalers Market Outlook, By Manually Operated Inhaler Devices (2021-2030) ($MN)
Table 102 Middle East & Africa Dry Powder Inhalers Market Outlook, By Digitally Operated Inhaler Devices (2021-2030) ($MN)
Table 103 Middle East & Africa Dry Powder Inhalers Market Outlook, By Indication (2021-2030) ($MN)
Table 104 Middle East & Africa Dry Powder Inhalers Market Outlook, By Pulmonary Arterial Hypertension (2021-2030) ($MN)
Table 105 Middle East & Africa Dry Powder Inhalers Market Outlook, By Chronic Obstructive Pulmonary Disease (COPD) (2021-2030) ($MN)
Table 106 Middle East & Africa Dry Powder Inhalers Market Outlook, By Asthma (2021-2030) ($MN)
Table 107 Middle East & Africa Dry Powder Inhalers Market Outlook, By Cystic Fibrosis (2021-2030) ($MN)
Table 108 Middle East & Africa Dry Powder Inhalers Market Outlook, By End User (2021-2030) ($MN)
Table 109 Middle East & Africa Dry Powder Inhalers Market Outlook, By Drug Stores (2021-2030) ($MN)
Table 110 Middle East & Africa Dry Powder Inhalers Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 111 Middle East & Africa Dry Powder Inhalers Market Outlook, By Hospitals (2021-2030) ($MN)
Table 112 Middle East & Africa Dry Powder Inhalers Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 113 Middle East & Africa Dry Powder Inhalers Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
Table 114 Middle East & Africa Dry Powder Inhalers Market Outlook, By Other End Users (2021-2030) ($MN)

Product Code: SMRC24451

According to Stratistics MRC, the Global Dry Powder Inhalers Market is accounted for $21.48 billion in 2023 and is expected to reach $33.60 billion by 2030 growing at a CAGR of 6.6% during the forecast period. Dry powder inhalers are medical devices that inhale powdered medication directly into the lungs. For the treatment of lung-related disorders and respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD), they are frequently prescribed. They don't need propellants to deliver the medication, in contrast to metered-dose inhalers (MDIs) and are also appropriate for people who might have trouble using MDIs because they do not require hand-breath coordination.

According to the article titled "Common Respiratory Disorders" published in April 2020 around 15% of older adults from asthma, chronic obstructive pulmonary disease, or another respiratory disorder.

Market Dynamics:

Driver:

Rising prevalence of respiratory disorders

The increasing prevalence of respiratory ailments such as cystic fibrosis, bronchitis, asthma, and chronic obstructive pulmonary disease (COPD) directly drives the need for efficient inhalation therapies. Since dry powder inhalers provide a practical and effective means of delivering medication directly to the lungs, they are in high demand as a treatment modality for these conditions. The increasing number of people suffering from respiratory disorders has led to a greater focus on symptom management, averting exacerbations, and enhancing overall disease management and these are used more frequently because of their critical role in sustaining long-term symptom control and offering immediate relief which drives the growth of the market.

Restraint:

High production costs and difficulty in application

Medication noncompliance brought on by difficulties managing the condition may lead to insufficient therapy, worsening of the illness, and higher medical expenses. If patients find Dry powder inhalers difficult to handle or load, they may choose to use alternative inhaler devices like nebulizers or metered-dose inhalers (MDIs). The market share and sales of dry powder inhalers may be impacted by this change in preferences. It may be necessary for healthcare providers to devote additional time and resources to instructing patients on proper handling and loading techniques. The complexity of patient education programs may increase due to this additional training requirement, which may also raise healthcare costs thus hamper the growth of the market.

Opportunity:

Increased focus on preventive care and disease management

Healthcare systems and providers are encouraged to concentrate on early intervention strategies due to the increased emphasis on preventive care. By offering prophylactic medication to manage symptoms and stop exacerbations and they contribute significantly to the management of respiratory conditions. Patient-centric care models are becoming more and more important as the focus shifts to illness prevention and management. Dry powder inhalers complement these care models by empowering patients to actively manage their respiratory conditions because they are easy to use and appropriate for self-administration.

Threat:

Availability of raw materials with intense competition

Insufficient compliance with drug regimens, such as dry powder inhalers, may result in insufficient treatment of respiratory disorders like COPD or asthma. Reduced lung function, an increase in the frequency of exacerbations, worsening symptoms, and an increased risk of hospitalization can all be caused by incomplete or irregular dosing. Moreover, demand of patient preferences, and prescription rates may all be impacted if patients fail to comply for a variety of reasons, such as inhaler difficulties. This might result in having a smaller market share than other kinds of inhalers.

COVID-19 Impact

Demand for respiratory medications, including those given through DPIs, surged during the pandemic as a result of increased awareness of respiratory health and worries about lung health brought on by COVID-19. Patients with long-term respiratory disorders tried to get access to the drugs they needed and continue their treatment plans. There was a move toward at-home medication self-administration due to limitations on mobility and visits to medical facilities. Due to their self-administration capabilities and ease of use, DPIs have become the go-to choice for treating respiratory disorders when regular clinic visits are not feasible.

The multi dose dry powder inhalers segment is expected to be the largest during the forecast period

The multi dose dry powder inhalers segment is estimated to have a lucrative growth, as they are used to administer powdered medication directly into the lungs. They usually use a reservoir that holds multiple doses of the powdered medication, allowing patients to take multiple doses over time. They enable the device to be preloaded with multiple doses, giving patients dosage flexibility and the ability to take their recommended doses at predetermined intervals. In order to meet patient needs and enhance treatment outcomes, manufacturers in this market sector are constantly innovating, concentrating on bettering drug delivery systems, ergonomics of devices, and dose accuracy.

The digitally operated inhaler devices segment is expected to have the highest CAGR during the forecast period

The digitally operated inhaler devices segment is anticipated to witness the highest CAGR growth during the forecast period, because digitally operated inhaler devices are a new and creative segment. Digital technology in these inhalers enables improved features like data tracking, connectivity, and better patient adherence to prescription schedules. Thus, the goal of adding digital components to inhaler devices is to enhance the way respiratory diseases like chronic obstructive pulmonary disease (COPD) and asthma are managed. Because digitally operated inhalers collect data on individual patient responses to treatment and inhaler usage patterns, they can support personalized medicine approaches thus boosting the growth of the market.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to the as a result of numerous government programs and healthcare regulations targeted at enhancing respiratory health and illness management. Adoption of DPIs and other effective inhalation therapies is frequently encouraged by supportive policies. Patient adherence and management are improved by the combination of DPIs with digital technologies, such as smart inhalers that provide features like dose tracking, reminders, and connectivity. The evolution of the market is driven by this patient-centric approach.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period, owing to the incidence of respiratory conditions such as asthma and COPD has been increasing, which has increased the need for efficient inhalation treatments. DPIs provide a practical and effective means of administering medicine to treat these ailments. Moreover, the market has grown as a result of ongoing innovations in drug delivery systems, formulations, and DPI designs. To increase medication adherence and efficacy, manufacturers are always working to create DPIs that are more portable, user-friendly, and efficient.

Key players in the market:

Some of the key players profiled in the Dry Powder Inhalers Market include GlaxoSmithKline Plc, Boehringer Ingelheim GmbH, Cipla Limited, Chiesi Farmaceutici S.p.A, AptarGroup, Inc., Iconovo AB, Mylan N.V, Pharmaxis, Teva Pharmaceutical Industries Limited, AstraZeneca Plc, Novartis AG, Elpen S.A, Vectura Group Plc, Beximco Pharmaceuticals Ltd, Hovione, MannKind Corporation, Sava Healthcare Ltd, 3M Company and DPI Co., Ltd.

Key Developments:

In October 2023, GSK enters agreement to obtain exclusive license for JNJ-3989 to expand the development of bepirovirsen. There is high unmet need in CHB with an estimated 300 million people living with the disease and a less than 3-7% functional cure rate with current treatment options.

In October 2023, GSK launches £6m programme to boost STEM career progression for young people from under-represented groups in the UK. New research reveals a nationwide focus on STEM mentoring of under-represented groups could boost individual incomes.

In October 2023, Boehringer Ingelheim and ZEISS join forces to early detect eye diseases and prevent vision loss. The partnership brings together their leading expertise in ophthalmological technology, data analytics, algorithms, and the development of treatments to detect early and treat retinal diseases before irreversible loss of vision occurs

Products Covered:

Multi Dose Dry Powder Inhalers
Single Dose Dry Powder Inhalers

Functions Covered:

Manually Operated Inhaler Devices
Digitally Operated Inhaler Devices

Indications Covered:

Pulmonary Arterial Hypertension
Chronic Obstructive Pulmonary Disease (COPD)
Asthma
Cystic Fibrosis

End Users Covered:

Drug Stores
Retail Pharmacies
Hospitals
Online Pharmacies
Ambulatory Surgical Centers
Other End Users

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Dry Powder Inhalers Market, By Product

5.1 Introduction
5.2 Multi Dose Dry Powder Inhalers
5.3 Single Dose Dry Powder Inhalers

6 Global Dry Powder Inhalers Market, By Function

6.1 Introduction
6.2 Manually Operated Inhaler Devices
6.3 Digitally Operated Inhaler Devices

7 Global Dry Powder Inhalers Market, By Indication

7.1 Introduction
7.2 Pulmonary Arterial Hypertension
7.3 Chronic Obstructive Pulmonary Disease (COPD)
7.4 Asthma
7.5 Cystic Fibrosis

8 Global Dry Powder Inhalers Market, By End User

8.1 Introduction
8.2 Drug Stores
8.3 Retail Pharmacies
8.4 Hospitals
8.5 Online Pharmacies
8.6 Ambulatory Surgical Centers
8.7 Other End Users

9 Global Dry Powder Inhalers Market, By Geography

9.1 Introduction
9.2 North America
- 9.2.1 US
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 Italy
- 9.3.4 France
- 9.3.5 Spain
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 New Zealand
- 9.4.6 South Korea
- 9.4.7 Rest of Asia Pacific
9.5 South America
- 9.5.1 Argentina
- 9.5.2 Brazil
- 9.5.3 Chile
- 9.5.4 Rest of South America
9.6 Middle East & Africa
- 9.6.1 Saudi Arabia
- 9.6.2 UAE
- 9.6.3 Qatar
- 9.6.4 South Africa
- 9.6.5 Rest of Middle East & Africa

10 Key Developments

10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies

11 Company Profiling

11.1 GlaxoSmithKline Plc
11.2 Boehringer Ingelheim GmbH
11.3 Cipla Limited
11.4 Chiesi Farmaceutici S.p.A
11.5 AptarGroup, Inc.
11.6 Iconovo AB
11.7 Mylan N.V
11.8 Pharmaxis
11.9 Teva Pharmaceutical Industries Limited
11.10 AstraZeneca Plc
11.11 Novartis AG
11.12 Elpen S.A
11.13 Vectura Group Plc
11.14 Beximco Pharmaceuticals Ltd
11.15 Hovione
11.16 MannKind Corporation
11.17 Sava Healthcare Ltd
11.18 3M Company
11.19 DPI Co., Ltd.

ドライパウダー吸入器の2030年までの市場予測：製品別、機能別、適応症別、エンドユーザー別、地域別の世界分析

Dry Powder Inhalers Market Forecasts to 2030 - Global Analysis By Product (Multi Dose Dry Powder Inhalers and Single Dose Dry Powder Inhalers), Function, Indication, End User and By Geography

COVID-19影響

最大のシェアを占める地域

CAGRが最も高い地域：

無料のカスタマイズサービス

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

目次

第1章 エグゼクティブサマリー

第2章 序文

第3章 市場動向分析

第4章 ポーターのファイブフォース分析

第5章 世界のドライパウダー吸入器市場：製品別

第6章 世界のドライパウダー吸入器市場：機能別

第7章 世界のドライパウダー吸入器市場：適応症別

第8章 世界のドライパウダー吸入器市場：エンドユーザー別

第9章 世界のドライパウダー吸入器市場：地域別

第10章 主な発展

第11章 企業プロファイル